664
Views
66
CrossRef citations to date
0
Altmetric
Review

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review

, , , &
Pages 57-67 | Published online: 06 Jan 2016

References

  • RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
  • SheitmanBBLiebermanJAThe natural history and pathophysiology of treatment resistant schizophreniaJ Psychiatr Res1998323–41431509793867
  • LiebermanJASheitmanBChakosMThe development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspectiveJ Clin Psychopharmacol1998182 suppl 120S24S9555612
  • HegelstadWTLarsenTKAuestadBLong-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcomeAm J Psychiatry2012169437438022407080
  • PenttilaMJaaskelainenEHirvonenNDuration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysisBr J Psychiatry20142052889425252316
  • Alvarez-JimenezMParkerAGHetrickSEPreventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosisSchizophr Bull201137361963019900962
  • EmsleyRChilizaBAsmalLThe nature of relapse in schizophreniaBMC Psychiatry2013135023394123
  • LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607
  • MarshallMRathboneJEarly intervention for psychosisCochrane Database Syst Rev20116CD00471821678345
  • ZipurskyRBMenezesNMStreinerDLRisk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic reviewSchizophr Res20141522–340841423972821
  • VenturaJSubotnikKLGuzikLHRemission and recovery during the first outpatient year of the early course of schizophreniaSchizophr Res20111321182321764563
  • GreenMFKernRSBraffDLNeurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?Schizophr Bull200026111913610755673
  • LeesonVCBarnesTRHuttonSBIQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosisSchizophr Res20091071556018793828
  • RobinsonDGWoernerMGMcMenimanMSymptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorderAm J Psychiatry2004161347347914992973
  • KeefeSEHarveyPDCognitive impairment in schizophreniaGeyerMAGrossGNovel Antischizophrenia Treatments, Handbook of Experimental Pharmacology 2013HeidelbergSpringer Verlag20121139
  • ChenEYHuiCLLamMMMaintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trialBMJ2010341c402420724402
  • EmsleyROosthuizenPKoenLRemission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injectionInt Clin Psychopharmacol200823632533118854720
  • LiebermanJAPhillipsMGuHAtypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazineNeuropsychopharmacology2003285995100312700715
  • SchoolerNRabinowitzJDavidsonMRisperidone and haloperidol in first-episode psychosis: a long-term randomized trialAm J Psychiatry2005162594795315863797
  • WunderinkLNienhuisFJSytemaSGuided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcomeJ Clin Psychiatry200768565466117503973
  • Crespo-FacorroBRodriguez-SanchezJMPerez-IglesiasRNeurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparisonJ Clin Psychiatry200970571772919389335
  • CuestaMJJalonEGCamposMSCognitive effectiveness of olanzapine and risperidone in first-episode psychosisBr J Psychiatry2009194543944519407274
  • DavidsonMGalderisiSWeiserMCognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)Am J Psychiatry2009166667568219369319
  • KeefeRSSeidmanLJChristensenBKLong-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisBiol Psychiatry20065929710516140282
  • KeefeRSSweeneyJAGuHEffects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparisonAm J Psychiatry200716471061107117606658
  • OlivierMRKillianSChilizaBCognitive performance during the first year of treatment in first-episode schizophrenia: a case-control studyPsychol Med201545132873288325998030
  • PurdonSEJonesBDStipENeuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophreniaArch Gen Psychiatry200057324925810711911
  • CsernanskyJGMahmoudRBrennerRA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophreniaN Engl J Med20023461162211777998
  • GaebelWSchreinerABergmansPRelapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trialNeuropsychopharmacology201035122367237720686456
  • KasperSLermanMNMcQuadeRDEfficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophreniaInt J Neuropsychopharmacol20036432533714609439
  • PigottTACarsonWHSahaARAripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week studyJ Clin Psychiatry20036491048105614628980
  • RuhrmannSKisslingWLeschOMEfficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptomsProg Neuropsychopharmacol Biol Psychiatry20073151012102217412473
  • TakeuchiHSuzukiTRemingtonGEffects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot studySchizophr Bull201339599399823821768
  • BilderRMGoldmanRSVolavkaJNeurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorderAm J Psychiatry200215961018102812042192
  • RobertsDLPennDLCorriganPAntipsychotic medication and social cue recognition in chronic schizophreniaPsychiatry Res20101781465020452678
  • LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 suppl15615000267
  • GitlinMNuechterleinKSubotnikKLClinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophreniaAm J Psychiatry2001158111835184211691689
  • TiihonenJHaukkaJTaylorMA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
  • BilderRMGoldmanRSRobinsonDNeuropsychology of first-episode schizophrenia: initial characterization and clinical correlatesAm J Psychiatry2000157454955910739413
  • HoffALSvetinaCShieldsGTen year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophreniaSchizophr Res2005781273415964177
  • WangCHLiYYangJA randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophreniaSchizophr Res20131441–312913523352776
  • Schizophrenia Working Group of the Psychiatric Genomics CBiological insights from 108 schizophrenia-associated genetic lociNature2014511751042142725056061
  • MaierRMoserGChenGBJoint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorderAm J Hum Genet201596228329425640677
  • McFarlaneWRCookWLDowningDPortland identification and early referral: a community-based system for identifying and treating youths at high risk of psychosisPsychiatr Serv201061551251520439374
  • KnowlesEEDavidASReichenbergAProcessing speed deficits in schizophrenia: reexamining the evidenceAm J Psychiatry2010167782883520439390
  • TrusheimMRBerndtERDouglasFLStratified medicine: strategic and economic implications of combining drugs and clinical biomarkersNat Rev Drug Discov20076428729317380152